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As men age, the prostate gland can enlarge to benign
hyperplasia. Enlargement of the prostate can constrict
the urethra, which can reduce urinary flow rates and
cause urinary hesitancy, urgency, increased frequency,
dysuria, and urinary tract infection. In addition to
the mechanical component caused by the physically
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This study was carried out to obtain information on the efficacy and safety of the controlled release
formulation of the doxazosin Gastrointestinal Therapeutic System (GITS) in Taiwanese subjects with
benign prostatic hyperplasia (BPH). Studies of doxazosin in Asian populations for this indication
have lacked data particularly from Taiwan. This was an 8-week, post-marketing, open-label, non-
comparative study. Eighty male subjects (mean age=64 years) with BPH received doxazosin GITS
4mg once daily. At week 4, subjects who achieved an increase in maximum urinary flow rate (Qmax)
of ≥3mL/s and a ≥30% reduction in the total International Prostate Symptom Score (IPSS) continued
on doxazosin GITS 4 mg for the remaining 4 weeks; all other subjects were up-titrated to 8 mg once
daily. Change from baseline at weeks 4 and 8 (primary endpoint) in IPSS and Qmax was evaluated
using two-sided paired t tests for the intent-to-treat population. Safety was assessed throughout the
study. A total of 53 (66.3%) subjects completed the study. Baseline Qmax and IPSS were 10.7±3.4mL/s
and 20.6±5.4, respectively. At week 8, a significant increase from baseline in Qmax of 3.3±4.6 mL/s
(95% confidence interval = 2.2–4.4, p < 0.001) and a significant decrease in total IPSS of –8.9 ± 7.0
(95% confidence interval = –10.5 to –7.3, p < 0.001) was observed. The most common treatment-
related adverse event was dizziness. Doxazosin GITS 4 mg per day (with an 8-mg titration step)
effectively improved symptoms of BPH. The results from this study provide further information for
clinicians on the use of doxazosin GITS for the treatment of BPH, particularly in Taiwanese patients.
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enlarged prostate, a dynamic component caused by
variations in the tone of the prostate smooth muscle
contributes to the obstruction. This tone is controlled
by the α-1 adrenergic receptors of the sympathetic
nervous system. Selective α-1 inhibitors, such as dox-
azosin, have been shown in several clinical trials to
improve urinary function and clinical symptoms of
subjects with benign prostate hyperplasia (BPH) [1,2].
The doxazosin Gastrointestinal Therapeutic System
(GITS) is a controlled release formulation. It has been
developed to produce a peak plasma concentration
with no higher than the 1-mg dose of immediate-
release doxazosin, while achieving greater overall
systemic exposure. Moreover, curative levels can be
achieved more rapidly with this formulation without
the addition of excessive titration steps [3]. Doxazosin
GITS has demonstrated efficacy, particularly for im-
provement of symptom scores and increase in maxi-
mum urinary flow (Qmax), as well as demonstrating
benefits on quality of life (QoL) [4,5]. The efficacy and
tolerability of 4-mg and 8-mg single doses of dox-
azosin GITS have been compared with a single dose
of 1 mg immediate release doxazosin in subjects with
mild-to-moderate hypertension, which results in simi-
lar outcomes [2].
The prevalence of BPH is difficult to determine
because a standardized definition is lacking; however,
the manifestation of lower urinary tract symptoms is
widely accepted [6,7]. Some clinical estimates of BPH
prevalence range from 80% in subjects aged > 80 years
in the United States [8] to 63% in those aged > 70 years
in an Asian population [9]. Surgical therapy has been
associated with higher treatment failure rates, cou-
pled with greater costs over the long term, therefore,
effective and tolerable medical treatment is highly
sought [10,11].
Although data are available on doxazosin GITS
for the treatment of BPH in many western popula-
tions, there remain limited data in Asian populations,
particularly in Taiwan. This study was designed to
evaluate the safety and efficacy of doxazosin GITS in
Taiwanese subjects with BPH.
METHODS
Study design
This was a post-marketing open-label study conducted
at five centers in Taiwan. Subjects were required to
attend the center on three occasions: baseline, week 4,
and week 8. All subjects were initiated on doxazosin
GITS 4 mg once daily to be taken at breakfast. At
week 4, an efficacy response-based dose titration oc-
curred: subjects who achieved an increase in Qmax of
≥ 3 mL/s and a ≥ 30% reduction in the total Interna-
tional Prostate Symptom Score (IPSS) from baseline
continued on doxazosin GITS 4 mg for the remainder
of the study; all other subjects were up-titrated to
doxazosin GITS 8 mg once daily for the remainder of
the study. The 8-week duration was chosen because
previous studies have shown that most changes in
total IPSS and Qmax are rapid and occur within the
initial 8 weeks of doxazosin GITS treatment [12].
Inclusion and exclusion criteria
This study was conducted in accordance with the 
latest version of the Declaration of Helsinki in 2008.
The protocol (study code: A0351063) was approved
by the Institutional Review Board at each center and
written informed consent was obtained from each
subject as a condition of entry.
We enrolled Taiwanese male subjects aged 50–80
years with a primary diagnosis of BPH, which was
defined an enlarged prostate (confirmed by digital rec-
tal examination and/or B-mode ultrasound), a baseline
IPSS score ≥ 12, and a baseline Qmax of 5–15 mL/s in
a total voided volume ≥ 150 mL. Subjects who had
previous prostate surgery or those who had a stent,
microwave thermotherapy, and/or balloon dilation
within the previous 6 months were excluded. Indi-
viduals who presented with known or suspected pros-
tate malignancy, or prostate specific antigen (PSA)
levels > 10 ng/mL, were also excluded.
Measurements
Efficacy was assessed using a subject-completed IPSS
questionnaire and Qmax at baseline, week 4, and week
8 (primary evaluations). The IPSS questionnaire com-
prised of two components: symptom score and QoL.
At each visit, Qmax was determined using a urinary
flow meter. Other efficacy assessments included post-
void residual urine volume, as determined by B-mode
ultrasound at each visit. The efficacy response was
classified as the proportion of subjects who achieved
an increase in Qmax of ≥3mL/s and a ≥30% reduction
in total IPSS score. Safety assessment included adverse
events, treatment discontinuation, clinical laboratory
tests, and physical examination at baseline and week 8.
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Vital signs (sitting blood pressure and heart rate) were
measured at each visit.
Statistical analysis
Sample size calculations were based on a significance
level of 2.5% to ensure that the overall type I error
did not exceed 5% for both of the primary endpoints.
Assuming a 20% attrition rate, a sample size of 80
subjects would provide 95% power to detect a differ-
ence from baseline of four units in the total IPSS [stan-
dard deviation (SD): 8 units), and 85% power to detect
a difference from baseline of 3 mL/s (SD: 7 mL/s) 
in Qmax.
The intent-to-treat (ITT) population (subjects who
took at least one dose of study medication and pro-
vided at least one post-baseline efficacy measure) and
the per-protocol population (ITT subjects without
major protocol violations who were compliant with
taking study medication, and had both primary end-
points measured at day 26 or thereafter) were used to
test the primary efficacy endpoints. Evaluation of the
mean change from baseline to the end of the study
(week 8) was conducted on total IPSS and Qmax using
two-sided paired t tests at the 2.5% significance level.
Secondary efficacy endpoints were analyzed using
paired t tests for the ITT population. If a subject with-
drew, the last available post-baseline observation was
carried forward and used in the analyses at weeks 4
and 8. Mean change, ± SD or p values and 95% confi-
dence intervals (CIs) are presented.
Standard summaries of safety parameters as de-
fined by the sponsor’s worldwide safety standards
were generated for the safety population (i.e. all sub-
jects who took at least one dose of study medication).
Compliance was assessed at each visit by calculating
the ratio between the total dosage taken and the total
dosage that should have been taken during follow-up.
Non-compliance was defined as taking <80% or >120%
of study treatment.
RESULTS
Participants
A total of 90 male Asian subjects from five centers
were screened: 80 (100%) were treated with doxazosin
GITS, and 53 (66.3%) completed the study. Subject dis-
position is presented in the Figure. The mean age was
64 years (range, 49–84 years), and the mean duration
of BPH at baseline was 2.2 years (range, 0–11.9 years).
The mean baseline PSA level was 2.3 ± 2.5 ng/mL.
Hypertension (n = 16, 20.0%), diabetes (n = 9, 11.3%),
and urethra and urinary tract disorders (n = 8, 10.0%)
were the most common disorders present at baseline.
Concomitant medications were taken by 47 (58.8%)
subjects; the most common of which were antacids
Figure. Study flow chart. GITS = gastrointestinal therapeutic system; AE = adverse event; ITT = intent to treat; PP = per protocol;
Inc/exc = inclusion/exclusion.
Screened (n = 90)
Assigned to Doxazosin GITS (n = 80)
Treated with Doxazosin GITS (n = 80)
Discontinued (n = 27; 33.8%)
AE due to study drug (n = 10; 12.5%)
Protocol violations (n = 16; 20.0%)
Subject defaulted (n = 1; 1.3%)
Excluded from ITT analysis (n = 5)
No post-baseline efficacy measure (n = 5)
Excluded from PP analysis (n = 29)
Not in ITT (n = 5)
Inc/exc criteria violation (n = 15)
Primary efficacy endpoints not collected after/on
Day 26 and non-compliant (n = 5)
Prohibited medications taken (n = 4)
Analyzed
Safety (n = 80; 100%)
ITT population (n = 75; 93.8%)
PP population (n = 51; 63.8%)
Completed (n = 53; 66.3%)
Excluded (n = 10)
Did not meet inclusion criteria (n = 9)
No longer willing to participate (n = 1)
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(16%), anti-inflammatory analgesics (15%), calcium
channel blockers (11%), and oral antidiabetic drugs
(11%).
Study treatment
The median duration of treatment was 53 days
(range, 1–62 days). Thirty (38%) subjects were up-
titrated to doxazosin GITS 8 mg at week 4, and 24
(30%) remained on doxazosin GITS 4 mg. The com-
pliance (80–120%) to study treatment at each visit
was high (94–98%), and the overall mean compliance
was 95 ± 15.3%.
IPSS
The absolute mean baseline total IPSS for the ITT pop-
ulation was 20.6 ± 5.4. Doxazosin GITS significantly
improved (decreased) the total IPSS from baseline to
week 8 by −8.9 ± 7.0 (p < 0.001, 95% CI = 10.5 to −7.3).
Furthermore, this improvement was evident as early
as week 4 (Table 1). A similar improvement was
observed for the per protocol analysis population at
week 8: change from baseline to −10.6 ± 6.4 (p < 0.001;
95% CI = −12.4 to −8.8).
Qmax
Statistically significant mean increases from baseline
in Qmax were observed at week 8 following treatment
with doxazosin GITS for the ITT and per protocol
populations. Table 2 presents the baseline absolute
mean and week 4 and 8 changes from baseline for both
population groups. The majority of increases in Qmax
occurred by week 4: change from baseline was 3.2 ±
4.7 mL/s (p < 0.001).
Urine volume
The change in post-void residual volume did not reach
statistical significance at any time point, although it
decreased (improved) from a mean baseline value of
40.3 ± 53.3 mL at week 4 by 9.4 ± 51.7 mL and at week
8 by 9.3 ± 49.5 mL.
QoL
Doxazosin GITS produced a significant decrease (im-
provement) in QoL score at weeks 4 and 8. The mean
baseline QoL index score was 4.1 ± 1.1. A mean change
from baseline to week 4 of −1.1 ± 1.4 (p < 0.001; 95%
CI = −1.4 to −0.8) was observed. This improvement
Table 2. Maximum urinary flow rates in different groups*
Qmax (mL/s) Absolute values Relative values† p 95% CI
ITT population
Baseline (n = 75) 10.7 ± 3.4
Week 4/LOCF (n = 68) 13.7 ± 4.3 3.2 ± 4.7 < 0.001 2.1–4.4
Week 8/LOCF (n = 68) 13.8 ± 4.6 3.3 ± 4.6 < 0.001 2.2–4.4
PP population (n = 51)
Baseline 10.5 ± 2.8
Week 4 13.9 ± 4.4 3.4 ± 4.9
Week 8/LOCF 14.1 ± 4.6 3.7 ± 4.7 < 0.001 2.3–5.0
*Data presented as mean ± standard deviation or confidence intervals; †changes from the baseline. Qmax = maximum urinary flow;
CI = confidence interval; ITT = intent to treat; PP = per protocol; LOCF = last post baseline observation carried forward.
Table 1. International Prostate Symptom Scores in different groups*
IPSS Absolute values Relative value† p 95% CI
ITT population (n = 75)
Baseline 20.6 ± 5.4
Week 4/LOCF 12.4 ± 6.4 –8.2 ± 7.6 < 0.001 –9.9 to –6.5
Week 8/LOCF 11.7 ± 6.3 –8.9 ± 7.0 < 0.001 –10.5 to –7.3
PP population (n = 51)
Baseline 21.7 ± 5.4
Week 4 11.4 ± 5.4 –10.3 ± 6.9
Week 8/LOCF 11.1 ± 5.6 –10.6 ± 6.4 < 0.001 –12.4 to –8.8
*Data presented as mean ± standard deviation or confidence intervals; †changes from the baseline. IPSS = International Prostate
Symptom Scores; CI = confidence interval; ITT = intent to treat; PP = per protocol; LOCF = last post baseline observation carried 
forward.
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advanced at week 8 to −1.3 ± 1.5 (p < 0.001; 95% CI =
−1.7 to –1.0)
Responders
The proportion of subjects who achieved a ≥ 3 mL/s
increase in Qmax and a ≥ 30% reduction in total IPSS
from baseline at weeks 4 and 8 was 34% and 43%,
respectively. A greater proportion of subjects on dox-
azosin GITS achieved a ≥ 30% reduction in total IPSS
from baseline at weeks 4 (64%) and 8 (67%) than sub-
jects who achieved a ≥ 3 mL/s increase in Qmax at
weeks 4 (41%) and 8 (51%).
Safety
A total of 49 adverse events were reported in 33 (41.3%)
subjects, and 35 adverse events reported in 23 (28.8%)
subjects were considered to be treatment-related. The
most commonly reported treatment-related adverse
event was dizziness (n = 12, 15.0%). Other treatment-
related events had a frequency of ≤ 5%; the most 
frequent of which were chest pain, pruritus, dry mouth,
and peripheral edema (all of which had a frequency of
≥ 2%). Ten (12.5%) subjects permanently discontinued
treatment due to related adverse events; all subjects
were on doxazosin GITS 4 mg at the time of discon-
tinuation. Eight (10.0%) subjects discontinued due to
dizziness, which might have been experienced alone or
in combination with other adverse events. Only two
treatment-related adverse events were reported as
severe: dizziness and sexual dysfunction. One (1.3%)
subject experienced acute pancreatitis and exacerbation
of gouty arthritis, both of which were reported as seri-
ous adverse events that were not related to study treat-
ment; the subject recovered and remained in the study.
DISCUSSION
The aim of this study was to evaluate the efficacy and
safety of doxazosin GITS 4 mg per day (with an 8 mg/
day titration step) in a Taiwanese population with BPH.
The results showed significantly marked improve-
ments from baseline for the primary efficacy endpoints
and a number of the secondary efficacy endpoints. 
In addition, benefits in QoL and a favorable safety
profile were observed.
The total IPSS was significantly improved from
baseline by –8.9 with doxazosin GITS at week 8. IPSS
is a validated tool for assessing symptom frequency
and severity, and is widely recognized as the interna-
tional standard [7]. Doxazosin GITS decreased the
mean baseline total IPSS from a classification of severe
(20.6; severe 20–35) to moderate (11.7; moderate 8–19),
as determined by the American Urological Association
[13], within 8 weeks. Furthermore, this result was ob-
served as early as week 4. The results of this study are
comparable to those published from other studies of
doxazosin GITS in western populations in which total
IPSS improvements of –8.1 [1] and –8.0 [14] have been
reported. It is worth noting that the IPSS improvements
shown in these western populations were observed
after 13 weeks of treatment. However, a comparable
improvement was observed after only 4 weeks in our
Taiwanese population.
The proportion of subjects who achieved a ≥3mL/s
increase in Qmax and a ≥ 30% reduction in total IPSS
(responders) from baseline at weeks 4 and 8 was 34%
and 43%, respectively. These results are similar to those
observed by Kirby et al, who documented that 32% of
subjects achieved both of these endpoints at week 13
[2]. A greater proportion of subjects achieved a ≥ 30%
reduction in total IPSS from baseline at weeks 4 (64%)
and 8 (67%) than subjects who achieved a ≥ 3 mL/s
increase in Qmax at weeks 4 (41%) and 8 (51%).
Chung et al reported that 84% of subjects achieved a
≥ 30% reduction in IPSS from baseline at week 12 with
doxazosin 2, 4 or 8 mg per day [15]. The higher figure
is probably explained by the longer duration of treat-
ment compared with the present study. Doxazosin
GITS has demonstrated efficacy for up to 13 weeks,
and further investigation is required to establish its
efficacy in the longer term.
Further to the improvements in efficacy measures,
doxazosin GITS also demonstrated benefits in QoL as
measured by the IPSS questionnaire. The change from
baseline in QoL after 2 months of treatment with dox-
azosin GITS was –1.3, which is comparable with the
3–9-month QoL results (change from baseline, –1.25)
presented for doxazosin in a recent review of all α-
blockers [16]. As prevalence of BPH is increasing as a
result of an aging population, agents that improve
symptoms as well as QoL are increasingly important.
Individuals with BPH commonly report higher
levels of PSA, possibly due to the disruption and
change in volume of the prostate. The Medical Therapy
of the Prostatic Symptoms (MTOPS) trial observed that
baseline PSA level in the doxazosin treatment group
(mean baseline PSA = 2.4 ng/mL) was a predictor of
Doxazosin for benign prostate hyperplasia
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risk of clinical progression of BPH and invasive ther-
apy [17]. Subjects in this study had a mean baseline
PSA level of 2.3 ng/mL, which is similar to that in
previous studies.
In the current study, we observed a favorable safety
profile with doxazosin 4 and 8 mg per day. The most
common adverse event was dizziness, which was also
the most frequent reason for treatment discontinua-
tion. Dizziness is known to occur with α-blockers,
although differences in frequency have been shown
with different agents [16]. Dizziness has been reported
previously with doxazosin use [18,19], therefore, this
finding was not unexpected.
A few limitations must be noted for the present
study. The study was designed as an open-label, non-
comparative trial; however, the treatment effect
observed was similar to findings reported for placebo-
controlled studies. The present study had a relatively
short duration of 8 weeks, and longer-term studies in
this population are needed to establish a sustained
benefit over time.
In summary, this multicenter, open-label study
demonstrated that doxazosin GITS 4 mg per day (with
an 8 mg/day titration step) effectively improved uri-
nary flow and other symptoms of BPH in a Taiwanese
population. Statistically significant improvements were
observed in the majority of efficacy measures, as early
as week 4, and maintained at week 8. Additionally, sig-
nificant benefits were demonstrated in QoL, and dox-
azosin GITS was found to be safe and well-tolerated
in this study population. These data will provide fur-
ther information for clinicians on the use of doxa-
zosin GITS for the treatment of BPH, particularly in
Taiwanese patients.
ACKNOWLEDGMENTS
This study was funded by Pfizer. Manjula Schou is 
an employee of Pfizer. Many thanks to all study team
members from Pfizer Taiwan and the Phase 3b/4Unit
Asia, Pfizer Global Research and Development,
Sydney, Australia for their invaluable contributions
to the study design, conduct, and reporting. Andrea
Malcolm and Ruth O’Halloran of the Phase 3b/4Unit
Asia provided medical writing assistance during the
production of this manuscript. The authors and study
team extend their gratitude to the subjects who partic-
ipated in this study.
REFERENCES
1. Gratzke P, Kirby RS. Doxazosin in the gastrointestinal
therapeutic system (GITS) and doxazosin standard in
patients with benign prostatic hyperplasia. Double-
blind trial of efficacy and tolerability. Fortschr Med Orig
2000;118(Suppl):83–92. [In German]
2. Kirby RS, Andersen M, Gratzke P, et al. A combined
analysis of double-blind trials of the efficacy and to-
lerability of doxazosin-gastrointestinal therapeutic
system, doxazosin standard and placebo in patients
with benign prostatic hyperplasia. BJU Int 2001;87:
192–200.
3. Chung M, Vashi V, Puente J, et al. Clinical pharmaco-
kinetics of doxazosin in a controlled-release gastro-
intestinal therapeutic system (GITS) formulation. Br J
Clin Pharmacol 1999;48:678–87.
4. Hernandez C, Duran R, Jara J, et al. Controlled-release
doxazosin in the treatment of benign prostatic hyper-
plasia. Prostate Cancer Prostatic Dis 2005;8:375–80.
5. Goldsmith D, Plosker GL. Doxazosin gastrointestinal
therapeutic system: a review of its use in benign prostatic
hyperplasia. Drugs 2005;65:2037–47.
6. Guidelines on Benign Prostatic Hyperplasia. European
Association of Urology 2006. Available at http://www.
uroweb.org/nc/professional-resources/guidelines/
online/ [Date accessed: September 25, 2008].
7. Guideline on the Management of Benign Prostatic
Hyperplasia (BPH). American Urological Association
2003. Available at http://www.guideline.gov/summary/
summary.aspx?ss=15&docid=3740&nbr=2966 [Date
accessed: September 25, 2008].
8. Fawzy A, Braun K, Lewis GP, et al. Doxazosin in the
treatment of benign prostatic hyperplasia in normo-
tensive patients: a multicenter study. J Urol 1995;154:
105–9.
9. Masumori N, Tsukamoto T, Rhodes T, et al. Natural
history of lower urinary tract symptoms in men—result
of a longitudinal community-based study in Japan.
Urology 2003;61:956–60.
10. Saigal CS, Movassaghi M, Pace J, et al. Economic eval-
uation of treatment strategies for benign prostatic
hyperplasia—Is medical therapy more costly in the
long run? J Urol 2007;177:1463–67.
11. Chung BH, Han KS, Kim JW, et al. Changing patterns
in the management of benign prostatic hyperplasia.
Eur Urol Suppl 2004;3:60. [Abstract]
12. Cardura ®XL Product Information. Pfizer Inc. Feb 2006
Available at: www.pfizer.com/files/products/uspi_
cardura_xl.pdf [Data accessed: October 19, 2009].
13. Barry MJ, Fowler FJ, Jr O’Leary MP, et al. The American
Urological Association symptom index for benign 
prostatic hyperplasia. The Measurement Committee of
the American Urological Association. J Urol 1992;148:
1549–57.
14. Andersen M, Dahlstand C, Hoye K. Double-blind trial
of the efficacy and tolerability of doxazosin in the
Kaohsiung J Med Sci October 2010 • Vol 26 • No 10538
G.H. Sun, K.H. Tsui, T.T. Wu, et al
gastrointestinal therapeutic system, doxazosin stan-
dard, and placebo in patients with benign prostatic
hyperplasia. Eur Urol 2000;38:400–9.
15. Chung BH, Hong SJ, Lee MS. Doxazosin for benign pro-
static hyperplasia: an open-label, baseline-controlled
study in Korean general practice. Int J Urol 2005;12:
159–65.
16. Irani-Jacques. Are all alpha-blockers created the same?
Eur Urol 2006;49:420–2.
17. McConnell JD, Roehrborn CG, Bautista OM, et al. 
The Long-Term Effect of Doxazosin, Finasteride, and
Combination Therapy on the Clinical Progression of
Benign Prostatic Hyperplasia. N Engl J Med 2003;349:
2387–98.
18. Chung BH, Sung J. Long-term follow-up study to eval-
uate the efficacy and safety of the doxazosin gastro-
intestinal therapeutic system in patients with benign
prostatic hyperplasia with or without concomitant
hypertension. BJU Int 2006;97:90–5.
19. Wilt TJ, MacDonald R. Doxazosin in the treatment of
benign prostatic hypertrophy: an update. Clin Interv
Aging 2006;1:389–401.
Kaohsiung J Med Sci October 2010 · Vol 26 · No 10 539
評估 Doxazosin GITS 對於前列腺肥大
病患的療效和安全性
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執行本試驗是為了收集 doxazosin GITS（經由控制緩慢釋放的劑型）在良性前列腺肥
大之台灣受試者的療效與安全性資料。Doxazosin 在亞洲族群的試驗缺少台灣單獨的
資料。此試驗為期 8 週、開放性、非對照研究。80 位有良性前列腺肥大（BPH）男性
受試者（平均年齡 64歲）接受 4 mg doxazosin GITS一天一次。在第 4 週達到最大尿
流速率（Qmax）增加 3mL/s 以上，且國際前列腺症狀評分（IPSS）減少 30% 以上的
受試者，接下來 4 週會繼續服用 4 mg doxazosin GITS。其他所有受試者則會調整劑量
至 8 mg doxazosin GITS一天一次。對意圖治療（intent-to-treat）族群是使用雙尾配對
樣本之 t檢驗（two-sided paired t tests），評估自基準點至第 4 週與第 8 週（主要終點）
的 IPSS與 Qmax的變化。試驗期間全程做安全性評估。共有 53 位受試者（66.3%）
完成試驗。基準點的 Qmax與 IPSS的總分，分別為 10.7 ± 3.4 mL/s 與 20.6 ± 5.4。
在第 8 週觀察到之 Qmax比基準點時顯著增加 3.3 ± 4.6mL/s（95% CI = 2.2–4.4；p 
< 0.001）；並且 IPSS總分顯著降低 –8.9 ± 7.0（95% CI = –10.5 to –7.3；p < 0.001）。
最常出現與治療相關的作用是暈眩。Doxazosin GITS 4 mg/day（與調整劑量至 8 mg）
能有效改善 BPH 的症狀。由本試驗獲得的結果將能提供臨床醫師更多使用 doxazosin 
GITS 治療 BPH 的資料，特別是對於台灣患者。
關鍵詞：前列腺肥大，可迅（doxazosin），腸胃治療系統，國際前列腺症狀評分，前列腺
（高雄醫誌 2010;26:532–9）
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